EUVIMEDUpptäck EUVIMED
Open access · CC BY 4.0

Limiting Trial‐and‐Error: Linker‐Based 2D Descriptor Analysis to Support Very Early Proteolysis‐Targeting Chimeras Design

Giulia Apprato iD, Serena Traversa iD, Giulia Caron iD, Giuseppe Ermondi iD

ChemMedChem · 2026

DOI: 10.1002/cmdc.70532 ↗

At a glance

Journal article in ChemMedChem, 2026. Written by Giulia Apprato and 3 co-authors. Institution: Department of Molecular Biotechnology and Health Sciences, University of Turin, Torino, Italy. Major MEDLINE topics: Drug Design. 16 references. The full text is freely available (open access, CC BY 4.0). Funded by: Università degli Studi di Torino, University of Turin in Italy.

AbstractSubjectsBibliografiska uppgifterCiteRelated studies

Abstract (original language)

Targeted protein degradation has emerged as a clinically validated therapeutic strategy, culminating in the recent FDA approval of the first proteolysis‐targeting chimeras (PROTAC) drug (VEPPANU). Within PROTACs, the linker plays a central role in modulating degradation efficiency as well as physicochemical and in vitro absorption, distribution, metabolism, and excretion properties, yet linker optimization still largely relies on empirical “linkerology” approaches. Here, we investigated whether simple 2D linker descriptors could provide informative insights for very early‐stage PROTAC design. Four matched PROTAC series, including both cereblon‐ and von Hippel–Lindau‐recruiting degraders, were retrospectively analyzed using a workflow combining the in‐house Bellerophon‐based linker extraction with principal component analysis. Selected descriptors captured linker hydrophobicity, polarity, flexibility, and topology and were correlated with experimental degradation, permeability, solubility, lipophilicity, protein binding, and metabolic stability data. In several datasets, linker‐dependent trends associated with the molecular properties of degraders and their degradation efficiency were identified, particularly for von Hippel–Lindau‐based PROTACs. Although the limited size of currently available datasets prevents broad generalization, this work highlights the potential of simple descriptor‐based analyses to support early candidate prioritization and reduce unnecessary synthetic efforts.

Subjects

MeSH terms (MEDLINE)

Drug DesignProteolysis Targeting ChimeraHumansProteolysisHydrophobic and Hydrophilic InteractionsVon Hippel-Lindau Tumor Suppressor ProteinMolecular Structure

Author keywords

PCAPROTACdegradationlinkermolecular properties

Substances

Proteolysis Targeting ChimeraVon Hippel-Lindau Tumor Suppressor Protein

Authors and institutions

  • Department of Molecular Biotechnology and Health Sciences, University of Turin, Torino, Italy.

ORCID profiles: Giulia Apprato, Serena Traversa, Giulia Caron, Giuseppe Ermondi

Funding

  • Università degli Studi di Torino
  • University of Turin in Italy

Cite

APA

Apprato, G., Traversa, S., Caron, G., & Ermondi, G. (2026). Limiting Trial‐and‐Error: Linker‐Based 2D Descriptor Analysis to Support Very Early Proteolysis‐Targeting Chimeras Design. ChemMedChem. https://doi.org/10.1002/cmdc.70532

Vancouver

Apprato G, Traversa S, Caron G, Ermondi G. Limiting Trial‐and‐Error: Linker‐Based 2D Descriptor Analysis to Support Very Early Proteolysis‐Targeting Chimeras Design. ChemMedChem. 2026. doi:10.1002/cmdc.70532

BibTeX
@article{Apprato2026,
  author = {Apprato, Giulia and Traversa, Serena and Caron, Giulia and Ermondi, Giuseppe},
  title = {Limiting Trial‐and‐Error: Linker‐Based 2D Descriptor Analysis to Support Very Early Proteolysis‐Targeting Chimeras Design},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.70532}
}
Start for free →